Department of Obstetrics & Gynecology, Carmel Medical Center.
Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.
Int J Gynecol Cancer. 2018 Sep;28(7):1311-1317. doi: 10.1097/IGC.0000000000001300.
Uterine papillary serous carcinoma (UPSC) is a highly aggressive subtype of endometrial carcinoma. Histopathologically, it resembles the pattern of serous papillary carcinoma of the ovary. Cancer antigen 125 (CA-125) is the most widely used biomarker in epithelial ovarian carcinoma. Its use in UPSC evaluation has yet to be determined. The purpose of this study was to investigate the significance of preoperative serum CA-125 as a prognostic factor in patients with UPSC.
The study cohort included all women with UPSC operated in our institution between January 2002 and June 2016. All patients underwent complete surgical staging. Preoperative CA-125 was reviewed and correlated with clinical and pathological parameters.
Sixty-one women met the study criteria. Median preoperative CA-125 was found to be significantly associated with disease stage. Patients with disease stages I to IV had median preoperative CA-125 levels of 12.15, 19.6, 22.6, and 177.5 U/mL (P < 0.0001) respectively. Levels of CA-125 were significantly associated with positive cytology (P < 0.0001), omental disease (P < 0.0001), pelvic or para-aortic lymph node metastasis (P < 0.0001), and adnexal involvement (P < 0.0001). The optimal cutoff that provided the best sensitivity and specificity for omental and parametrial involvement as well as positive cytology was 57.5 U/mL. For adnexal and lymph node involvement, the optimal cutoff value was 41.8 U/mL.
In patients with UPSC, preoperative CA-125 level correlates with known prognostic parameters of endometrial carcinoma and is associated with extrauterine involvement. These data should stimulate the need for further evaluation of the role of CA-125 in predicting recurrence and survival in UPSC.
子宫乳头状浆液性癌(UPSC)是一种高度侵袭性的子宫内膜癌亚型。组织病理学上,它类似于卵巢浆液性乳头状癌的模式。癌抗原 125(CA-125)是上皮性卵巢癌最广泛使用的生物标志物。其在 UPSC 评估中的应用尚未确定。本研究旨在探讨术前血清 CA-125 作为 UPSC 患者预后因素的意义。
研究队列包括 2002 年 1 月至 2016 年 6 月在我院接受 UPSC 手术的所有女性患者。所有患者均接受了完整的手术分期。回顾术前 CA-125 并与临床和病理参数相关。
61 名女性符合研究标准。中位术前 CA-125 与疾病分期显著相关。疾病分期 I 至 IV 期的患者术前 CA-125 中位水平分别为 12.15、19.6、22.6 和 177.5 U/mL(P < 0.0001)。CA-125 水平与细胞学阳性(P < 0.0001)、大网膜疾病(P < 0.0001)、盆腔或主动脉旁淋巴结转移(P < 0.0001)和附件受累(P < 0.0001)显著相关。最佳截断值为 57.5 U/mL,用于预测大网膜和附件受累以及细胞学阳性;最佳截断值为 41.8 U/mL,用于预测附件和淋巴结受累。
在 UPSC 患者中,术前 CA-125 水平与子宫内膜癌的已知预后参数相关,并与子宫外受累相关。这些数据应激发进一步评估 CA-125 在预测 UPSC 复发和生存中的作用的必要性。